# Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

> **NCT01280955** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mitchell Horwitz, MD** · enrollment: 41 (actual)

## Conditions studied

- Failure of Bone Marrow Graft

## Interventions

- **DRUG:** Plerixafor

## Key facts

- **NCT ID:** NCT01280955
- **Lead sponsor:** Mitchell Horwitz, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-09
- **Final completion:** 2015-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280955, "Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01280955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*